Skip to main content
Erschienen in: Esophagus 4/2020

04.09.2020 | Editorial

Will definitive chemoradiotherapy be a new normal for patients with resectable locally advanced esophageal cancer?

verfasst von: Hiroya Takeuchi

Erschienen in: Esophagus | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Excerpt

Nowadays, neoadjuvant chemotherapy or chemoradiotherapy (CRT) followed by esophagectomy is the standard of care for patients with resectable locally advanced esophageal cancer worldwide [13]. On the other hand, for patients unwilling to undergo esophagectomy, definitive CRT has been an alternative treatment for those with advanced esophageal cancer [4]. However, there are several problems to be resolved for conventional definitive CRT, such as a high incidence of late toxicities and poor survival. …
Literatur
1.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.CrossRef Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.CrossRef
2.
Zurück zum Zitat Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRef Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRef
3.
Zurück zum Zitat Van Hagen P, Hulchof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRef Van Hagen P, Hulchof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRef
4.
Zurück zum Zitat Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2–3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.CrossRef Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2–3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.CrossRef
5.
Zurück zum Zitat Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) Phase III trial of combined modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.CrossRef Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) Phase III trial of combined modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.CrossRef
Metadaten
Titel
Will definitive chemoradiotherapy be a new normal for patients with resectable locally advanced esophageal cancer?
verfasst von
Hiroya Takeuchi
Publikationsdatum
04.09.2020
Verlag
Springer Singapore
Erschienen in
Esophagus / Ausgabe 4/2020
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-020-00780-3

Weitere Artikel der Ausgabe 4/2020

Esophagus 4/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.